Quality Care - everyone, everytime
 

2.12 Lipid-regulating drugs

 

NICE TA181  Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease Jul 14
NICE CG71 Familial hypercholesterolaemia Aug 08 
Drug Safety Update CYP3A4 enzyme inhibitors can increase levels of simvastatin and an increased risk of rhabdomyolysis Jan 08 
Drug Safety Update Additional side effects related to statins Feb 08
Drug Safety Update Simvastatin - Increased risk of myopathy at high doses (80mg) May 10
Lipid Modification Guidance for Patients at "Highest Risk" of Cardiovascular Events   

 

1st          ATORVASTATIN     
1st        SIMVASTATIN (1st line up to 40mg)     
1st        FLUVASTATIN    
1st        PRAVASTATIN    
         ALIROCUMAB  NICE TA393 Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia  
         EVOLOCUMAB  NICE TA394 Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia  
2nd        ROSUVASTATIN    
2nd        CHOLESTYRAMINE     
2nd        FENOFIBRATE     
2nd        BEZAFIBRATE    
2nd        COLESEVELAM    
2nd        EZETIMIBE (Yellow)    

Nicotinic acid group

Awaiting decision following withdrawl of Tredaptive (Jan 2013)

Omega-3 fatty acid compounds

        OMACOR (Yellow)    

Related pages

Keep up to date with the latest Trust News

Our Performance

To see our latest performance and financial report click here.

Tell Us Your Views

Click here to find out how you can feedback to us about your experiences, along with how to raise any concerns, complaints or questions.